NCT07393659

A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment

A Phase 3b, Open-label, Multicenter, Continued Access Study for Participants Transitioning From ViiV Healthcare Sponsored or ViiV Healthcare Collaborative Parent Studies for HIV Treatment

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 183 (estimated)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to provide continued access to the study treatment for participants from previous ViiV Healthcare studies who are still benefiting from it and do not have local access after completing the parent study. This continued access will also allow further collection of safety data. Eligible participants are those who completed a ViiV Healthcare-sponsored or collaborative parent study and are currently experiencing clinical benefit. The Sponsor will periodically review the study to consider other treatment access options.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	Fostemsavir	Participants receive oral tablets with the dosages depending on the weight of the participants.
DRUG	Dolutegravir (DTG)/ Lamivudine (3TC)	Participants receive oral tablets with the dosages depending on the weight of the participants.

Timeline

• Start date: 2026-05-08
• Primary completion: 2030-12-30
• Completion: 2030-12-30
• First posted: 2026-02-06
• Last updated: 2026-02-06